Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives $41.78 Average Price Target from Analysts

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) have been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $41.7778.

A number of research firms recently weighed in on TEVA. Bank of America increased their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Barclays upped their target price on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Truist Financial raised their price target on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 21,258 shares of the business’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $35.31, for a total transaction of $750,619.98. Following the completion of the transaction, the executive vice president owned 63,647 shares in the company, valued at approximately $2,247,375.57. The trade was a 25.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Eliyahu Sharon Kalif sold 153,251 shares of the business’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total value of $5,457,268.11. Following the transaction, the executive vice president owned 172,184 shares of the company’s stock, valued at $6,131,472.24. This trade represents a 47.09% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 465,931 shares of company stock worth $16,332,989. 0.54% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Victrix Investment Advisors raised its stake in shares of Teva Pharmaceutical Industries by 9.5% during the second quarter. Victrix Investment Advisors now owns 7,850 shares of the company’s stock valued at $266,000 after purchasing an additional 681 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in Teva Pharmaceutical Industries by 128.1% in the second quarter. Assenagon Asset Management S.A. now owns 3,056,017 shares of the company’s stock worth $103,538,000 after purchasing an additional 1,716,315 shares during the period. GAMMA Investing LLC grew its position in Teva Pharmaceutical Industries by 19.6% in the 2nd quarter. GAMMA Investing LLC now owns 11,361 shares of the company’s stock valued at $385,000 after buying an additional 1,859 shares in the last quarter. Versant Capital Management Inc grew its position in Teva Pharmaceutical Industries by 15.8% in the 2nd quarter. Versant Capital Management Inc now owns 10,265 shares of the company’s stock valued at $348,000 after buying an additional 1,399 shares in the last quarter. Finally, CX Institutional acquired a new position in Teva Pharmaceutical Industries during the 2nd quarter valued at about $54,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $32.00 on Friday. Teva Pharmaceutical Industries has a 12 month low of $14.99 and a 12 month high of $37.35. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The stock has a fifty day moving average price of $33.76 and a 200 day moving average price of $32.70. The company has a market cap of $36.79 billion, a P/E ratio of 24.06, a PEG ratio of 3.38 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The company had revenue of $3.98 billion for the quarter. On average, research analysts forecast that Teva Pharmaceutical Industries will post 1.99 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.